Akkermansia Muciniphila — What It Is, Why It Matters and How to Increase It

Akkermansia muciniphila has been described as one of the most important bacteria in the human gut — not because it is the most abundant, but because of what it does. As a keystone species, its presence supports the entire gut ecosystem. Its absence is consistently linked to IBS, metabolic disease, inflammatory conditions, and — in one of the most significant findings in recent cancer research — failure to respond to immunotherapy. This article covers what the research actually shows, why Akkermansia matters for IBS specifically, and what you can do to support it.

What Is Akkermansia Muciniphila?

Akkermansia muciniphila is a gram-negative bacterium that lives in the mucus layer lining the human intestine. First identified and characterised in 2004 by Dutch microbiologist Muriel Derrien, it belongs to the phylum Verrucomicrobia — a relatively rare bacterial phylum that is distinct from the Firmicutes and Bacteroidetes that dominate most microbiome discussions.

What makes Akkermansia unusual is its food source. While most gut bacteria ferment dietary residues — fibre, carbohydrates, proteins that pass through from digestion — Akkermansia feeds on mucin, the glycoprotein that forms the gut's protective mucus layer. This is not destructive: the process of Akkermansia consuming older mucin signals goblet cells in the gut lining to produce fresh mucus, maintaining a healthy, continuously renewed protective barrier.

In a healthy gut, Akkermansia muciniphila typically constitutes between 1% and 5% of the total gut microbiome. It is considered a keystone species — a bacterium whose presence has a disproportionate positive impact on the broader gut ecosystem relative to its abundance. When Akkermansia levels fall significantly, the consequences extend well beyond the gut itself.

Akkermansia and IBS — The Gut Barrier Connection

The connection between Akkermansia and IBS centres on intestinal permeability — what is commonly referred to as "leaky gut." In IBS, particularly IBS-D (diarrhoea-predominant IBS), the tight junction proteins that seal the gaps between intestinal epithelial cells become compromised. This allows bacterial endotoxins — particularly lipopolysaccharide (LPS) — to leak into the bloodstream, triggering low-grade systemic inflammation and activating immune responses in the gut wall that worsen visceral hypersensitivity and alter gut motility.

Akkermansia muciniphila directly addresses this mechanism. By maintaining mucus layer thickness and stimulating the renewal of tight junction proteins, it reinforces the gut barrier against permeability. Studies consistently find that people with IBS — particularly IBS-D — have significantly lower Akkermansia abundance than healthy controls. Whether this depletion is a cause or consequence of IBS is not yet fully established, but the mechanistic pathway through which low Akkermansia could worsen IBS symptoms is well understood.

The Cancer Immunotherapy Finding

The most significant Akkermansia research to emerge in recent years has come not from gastroenterology but from oncology — and the findings are remarkable enough to have changed how researchers think about cancer treatment outcomes.

Immunotherapy — specifically immune checkpoint inhibitors that block PD-1 and PD-L1 proteins to activate the body's own immune cells against cancer — has been described as the first cancer treatment with the genuine potential to completely reverse advanced disease. However, only approximately 20% of patients respond to immunotherapy. For decades, researchers could not identify what distinguished responders from non-responders across gender, age, genetics, and comorbidities.

A landmark 2018 study published in Science by Routy et al. examined patients with lung and kidney cancers receiving PD-1 blockade immunotherapy. The study found that non-responding patients had significantly lower levels of Akkermansia muciniphila in their gut microbiome. When Akkermansia was administered orally to antibiotic-treated mice whose microbiomes had been disrupted, it restored their response to immunotherapy. The conclusion — that a single gut bacterium could influence whether a potentially life-saving cancer treatment worked or failed — was described by leading oncologists as one of the most significant microbiome findings of the decade.

A 2022 follow-up study in Nature Medicine by Derosa et al., examining patients with advanced non-small cell lung cancer, found that Akkermansia-positive patients had an objective response rate of 28% versus 18% in Akkermansia-negative patients. More significantly, baseline Akkermansia levels proved to be a better predictor of immunotherapy response than PD-L1 expression — the standard biomarker currently used in clinical oncology to determine which patients are likely to benefit from treatment.

Akkermansia, GLP-1 and Metabolic Health

Beyond gut barrier function and immunity, Akkermansia muciniphila has a direct role in metabolic health through its effect on GLP-1 — glucagon-like peptide 1, the hormone that regulates appetite, blood sugar, and insulin secretion.

Akkermansia stimulates intestinal L-cells to produce and release GLP-1. This is the same hormone pathway targeted by semaglutide (marketed as Ozempic for diabetes and Wegovy for weight loss) — the class of pharmaceutical GLP-1 receptor agonists that has dominated metabolic health discussions in recent years. The difference is mechanism: pharmaceutical GLP-1 agonists mimic the hormone externally; Akkermansia stimulates the body to produce more of its own.

A proof-of-concept clinical trial published in Nature Medicine (Plovier et al., 2017 / Depommier et al., 2019) supplemented insulin-resistant adults with either live or pasteurised Akkermansia muciniphila for three months. Participants showed significant improvements in insulin sensitivity, fasting glucose levels, blood cholesterol and liver enzyme markers. Pasteurised Akkermansia produced results equal to or greater than the live form — a finding that has shaped the supplement market significantly, as pasteurised preparations are far more stable and easier to manufacture.

GLP-1 receptors are present on blood vessels throughout the body — including the brain's vascular network — which means Akkermansia's GLP-1 stimulating effect has potential implications that extend beyond weight and blood sugar into cardiovascular and neurological health. This remains an emerging area of research.

How to Increase Akkermansia Naturally

Akkermansia muciniphila cannot be obtained directly from food — it is not present in fermented foods, yogurt, kefir, or other conventional probiotic sources. However, specific dietary compounds stimulate the gut to produce conditions in which Akkermansia thrives, primarily by increasing mucin secretion (providing more food for the bacterium) and by directly stimulating its growth.

What Depletes Akkermansia

Understanding what reduces Akkermansia is as important as knowing what increases it. Several common dietary and lifestyle factors consistently deplete it:

• Antibiotics — one of the most significant depletors. The Routy 2018 immunotherapy study specifically found that patients who had taken antibiotics in the months before immunotherapy had significantly worse outcomes, with Akkermansia depletion identified as a key mechanism. Antibiotics prescribed close to immunotherapy treatment are now an active area of oncological concern.
• Ultra-processed foods — emulsifiers commonly found in processed foods (carboxymethylcellulose, polysorbate-80) have been shown in research to disrupt the gut mucus layer and reduce Akkermansia abundance.
• Low-fibre diets — dietary fibre supports mucin production which feeds Akkermansia. A sustained low-fibre diet reduces the substrate available for mucin renewal.
• Excessive alcohol — particularly beer and spirits, which directly disrupt gut barrier function and microbiome composition.
• Long-term strict keto without dietary variety — the very low fibre intake of an improperly managed ketogenic diet can reduce Akkermansia over time, despite keto's other gut benefits.
• Chronic stress and poor sleep — both independently alter gut microbiome composition through the gut-brain axis, with Akkermansia among the bacteria most sensitive to stress-related disruption.

Akkermansia Supplements — Live vs Pasteurised

Akkermansia muciniphila supplements are now available in Ireland and the EU following Novel Food approval in 2021. Two forms exist:

Pasteurised (heat-killed) Akkermansia — the form used in the most rigorous human clinical trials, including the Plovier/Depommier proof-of-concept study. Heat treatment kills the bacterium but preserves key outer membrane proteins, particularly Amuc_1100, which interacts with Toll-Like Receptor 2 in the gut lining to produce metabolic and immune effects. Pasteurised preparations are significantly more stable, easier to store, and do not require the strict anaerobic manufacturing conditions of live forms. Clinical evidence suggests pasteurised Akkermansia is as effective as — and in some measures superior to — the live form.

Live Akkermansia — requires strict anaerobic manufacturing (oxygen kills the bacterium) and careful cold-chain storage. The theoretical advantage is colonisation potential — live bacteria may be better positioned to establish in the gut. However, the published clinical evidence for superiority over pasteurised forms in humans is not yet established.

The leading commercial products in Ireland and the EU include Pendulum (which uses a live formulation) and Metagenics (which uses a pasteurised formulation). Both are available online and through health food retailers. For deeper guidance on choosing a supplement, checking strain verification, EU Novel Food compliance and dosing, see akkermansia.ie.

Related Articles

15 June 2026 Gut Health

Probiotics and IBS — What the Research Shows

Read Article →

5 June 2026 Gut Health

The Gut-Brain Axis and IBS

Read Article →